The market value of MS therapy will reach 20 billion US dollars in 2024

Source: Xinkangjie 2015-10-12 according to global data, a research consulting company, the market value of multiple therapy will slowly increase from the current US $17.2 billion to US $20 billion in 2014, with a compound annual growth rate of 1.5% In a new report, global data claims that the increase in the market value of multiple therapies will mainly appear in the following 10 important markets: the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, Canada, China, India High quality drugs continue to be introduced to the market of multiple therapies, while the availability of new alternative drugs increases the treatment rate These two factors jointly drive the steady growth of the market value of multiple therapies Thomas Parker, a neurologist and ophthalmologist at GlobalData, said that the continuous updating of oral disease modification therapy (DMTs), which usually has higher annual treatment costs and improved compliance, and the increasing number of products available for oral disease modification therapy for progressive multiple sclerosis, will promote the increase of market value of multiple therapy in the expected time However, the market for this therapy is likely to stagnate between 2018 and 2020, mainly because the generic drugs of some heavyweight products have brought trauma to patented drugs For example, Teva's Copaxone (injected once a day) is the best-selling multiple sclerosis drug in the world In 2013, the global sales reached 4.33 billion US dollars, ranking the top 10 in the global multiple sclerosis (MS) drug sales in 2013 However, the Copaxone patent expires in the summer of 2015, when the drug will suffer a huge impact from cheap generic drugs Products currently in the R & D pipeline will offset the market erosion caused by generic drugs However, analysts pointed out that the market of multiple therapy will start to grow steadily from 2020, when the drugs in the R & D pipeline will continue to move to western countries, which, after offsetting the erosion brought by generic drugs, will promote the increase of market value to a certain extent In the report, global data lists eight drugs in the late stage of development, which are expected to enter the market of multiple sclerosis therapy by 2024 Among them, ocrelizumab of Roche / Genentech, ozanimod of celgene and zinbryta of EBV / parkkin are expected to bring the most lucrative profits "These highly effective drugs, which are still in the pipeline of development, are expected to have a significant impact because they may be popular with patients in a convenient way, such as simple oral preparations and injection types with less frequent injection times," explains Thomas Parker Global data predicts that by 2024, eight drugs in the later development pipeline will occupy 29.8% of the global multiple sclerosis therapy market, with a total sales volume of nearly $6 billion.